With high drug expenditure and a social health insurance system struggling to keep up, South Korea is risking the future of local generics manufacturers in a bid to contain rising costs. Adding to an abundance of existing drug price cuts, Datamonitor believes that this latest plan to reduce the prices of generics will substantially slow market growth in the country.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions